Inactief instrument

Andere talen HLS Therapeutics Inc Toronto S.E.

Aandelen

AM

CA05328X1015

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	09/05
HLS Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
HLS Therapeutics Brief: Q1 2024 revenue was US$12.5 million, Adjusted EBITDA was $2.7 million and cash from operations was $0.8 million	09/05
HLS Therapeutics Announces Q1 2024 Financial Results	09/05
HLS Therapeutics Inc Updates Consolidated Revenue Guidance for the Full Year 2024	09/05
HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call	25/04
HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	09/04
HLS Therapeutics Inc. Announces Reduce-IT Analysis Results Relating the Effects of VASCEPA	08/04
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	08/04
HLS Therapeutics Reports Q4 2023 Net Loss of US$5.4 Million; Provides 2024 Outlook, Credit Agreement Update	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
HLS Therapeutics Brief: Q4 2023 and fiscal 2023 product sales in Canada increased 11% and 10%, respectively, in CAD, compared to same periods in 2022	14/03
HLS Therapeutics Brief: Q4 2023 revenue was US$15.9 million, Adjusted EBITDA was $5.3 million and cash from operations was $3.7 million	14/03
HLS Therapeutics Announces Fiscal 2023 Financial Results	14/03
HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024	14/03
HLS Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/03
HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call	29/02
HLS Announces that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	07/02
HLS Therapeutics Says Vascepa Now Reimbursed by British Columbia's Provincial Drug Plan	06/02
HLS Therapeutics Brief: Announcing that Vascepa is now reimbursed by British Columbia's Provincial Drug Plan	06/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen HLS Therapeutics Inc Toronto S.E.

Aandelen

AM

CA05328X1015

Andere talen

Filters